

RITA Medical CEO to Present at the RBC Capital Markets 2006 Healthcare Conference

FREMONT, Calif., Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- RITA Medical Systems, Inc. (Nasdaq: RITA), a publicly-traded medical device company focused solely on cancer therapies, today announced that Joseph DeVivo, President & CEO of RITA Medical Systems, will participate in the panel discussion "Away From the Heart: Expanding the Role of Interventional Medicine" at the RBC Capital Markets 2006 Healthcare Conference. The presentation is scheduled for 12:30 p.m. Eastern Time on Wednesday, December 13, 2006 and will take place at the Westin New York at Times Square Hotel.

Attendance at the conference is by invitation only. RITA Medical will offer a live audio webcast of this presentation which may be accessed at the Company's website at www.ritamedical.com. An archived replay of the presentation will be made available as soon as practicable following the completion of the live presentation and will also be available at www.ritamedical.com for 30 days.

About RITA Medical Systems, Inc.

RITA Medical Systems develops, manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems and embolization products for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex® technology; tunneled central venous catheters; and safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The radiofrequency product line also includes the HABIB 4X resection device which coagulates a "surgical resection plane" and is designed to facilitate a fast dissection in order to minimize blood loss and blood transfusion during surgery. The proprietary RITA RFA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time for the palliation of pain associated with metastatic lesions involving bone. The Company also distributes LC Bead™ embolic microspheres in the United States. The LC Bead microspheres are injected into selected vessels to block the blood flow feeding a tumor, causing it to shrink over time, and are often used in combination with RFA. The RITA Medical Systems website is at www.ritamedical.com.

Contact:

EVC Group

Investors:

Doug Sherk

dsherk@evcgroup.com

Jenifer Kirtland

jkirtland@evcgroup.com

415-896-6820

Media:

Steve DiMattia

sdimattia@evcgroup.com

646-277-8706

RITA Medical Systems, Inc.

Stephen Pedroff, VP Marketing

Communications

510-771-0400

SOURCE RITA Medical Systems, Inc.

media, Steve DiMattia, +1-646-277-8706, or sdimattia@evcgroup.com, or investors, Doug Sherk, dsherk@evcgroup.com, or Jenifer Kirtland, jkirtland@evcgroup.com, both of EVC

Group, +1-415-896-6820, for RITA Medical Systems, Inc.; or Stephen Pedroff, VP
Marketing Communications of RITA Medical Systems, Inc., +1-510-771-0400

<http://www.ritamedical.com/>